Concurrent Technologies announced on Tuesday that it has approved a revised, lower-cost plan to expand manufacturing capacity ...
Acalabrutinib was associated with increased PFS and a 24% reduction in time to next treatment or death in long-term results. Concurrent acalabrutinib, bendamustine, and rituximab (ABR) in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback